| Bioactivity | Ziresovir (AK0529;RO-0529) is a potent, selective, and orally bioavailable respiratory syncytial virus (RSV) fusion (F) protein (RSV F) protein inhibitor. Ziresovir shows anti-RSV activity (EC50=3 nM) and highlights pharmacokinetics in animal species[1]. | ||||||||||||
| Target | RSV F protein (respiratory syncytial virus fusion protein)EC50: 3 nM (RSV F) | ||||||||||||
| Invitro | Ziresovir shows different efficacy in Wild Type (WT) and Mutant Strains RSV with EC50/EC90 values (μM) of 0.003/0.005 (WT), 2.1/10.0 (D486N), and >10/>10 (D489A), respectively[1].RO-0529 (100 nM; 4 d) inhibits RSV F protein-induced cell–cell fusion process, and suppresses the syncytia formation induced by the RSV F protein[1]. | ||||||||||||
| In Vivo | Ziresovir (12.5 mg/kg, 50 mg/kg; p.o.; twice daily; 4 d) results reduction of RSV titer in mouse lung[1]. Ziresovir (10 mg/kg; p.o.; single dose) exhibits good oral exposure and bioavailability with F(%) of 32% in male Wistar-Han rats[1]. Ziresovir (150 mg/kg; p.o.; single dose) demonstrates a high tissue distribution to lung than plasma in CD-1 Mice[1].Pharmacokinetics of Ziresovir in male Wistar-Han rats[1]Dose (mg/kg) | ||||||||||||
| Name | Ziresovir | ||||||||||||
| CAS | 1422500-60-4 | ||||||||||||
| Formula | C22H25N5O3S | ||||||||||||
| Molar Mass | 439.53 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Zheng X, et al. Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor. J Med Chem. 2019 Jul 11;62(13):6003-6014. |
Ziresovir
CAS: 1422500-60-4 F: C22H25N5O3S W: 439.53
Ziresovir (AK0529;RO-0529) is a potent, selective, and orally bioavailable respiratory syncytial virus (RSV) fusion (F)
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.